Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Teva Pharmaceutical Industries Ltd. (TEVA) vs United Therapeutics Corporation (UTHR)

Teva Pharmaceutical Industries Ltd. and United Therapeutics Corporation are both Drug Manufacturers Specialty & Generic companies. Teva Pharmaceutical Industries Ltd. is the larger, with a market value of $46.9B against $20.3B — 2.3× the size. United Therapeutics Corporation trades at the lower P/E: 15.7× against 62.2×. Teva Pharmaceutical Industries Ltd. grew revenue faster over the last twelve months: 4.13% against 2.49%. United Therapeutics Corporation has the higher net margin (41.6% vs 4.08%) and the higher return on invested capital (23.4% vs 4.58%). Across the 22 metrics below, United Therapeutics Corporation leads on 18 and Teva Pharmaceutical Industries Ltd. on 4.

Valuation

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
P/E 62.21 15.70 20.14
P/S 2.64 6.42 2.25
P/B 5.89 3.16 1.90
Price to free cash flow 32.59 18.62 16.54
EV/EBITDA 23.38 11.98 12.29
EV/Sales 3.38 5.67 2.56
Earnings yield 1.61% 6.37% (2.99%)
Free cash flow yield 3.07% 5.37% 0.00%

Profitability

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
Gross margin 52.46% 86.14% 53.94%
Operating margin 8.77% 44.44% 0.00%
Net margin 4.08% 41.56% 0.00%
Free cash flow margin 8.09% 34.65% 0.00%
Return on equity 9.69% 19.32% (0.40%)
Return on assets 1.77% 17.33% (3.32%)
Return on invested capital 4.58% 23.44% 0.00%

Growth

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 4.13% 2.49% 10.01%
EPS growth (last fiscal year) 183.45% 13.07% —
Revenue growth, 5-year CAGR 0.71% 16.50% 6.74%
Net income growth, 5-year CAGR 0.00% 20.99% 0.00%

Health

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
Debt to equity 2.14 0.00 0.05
Current ratio 0.88 5.73 2.31
Net debt to EBITDA 4.19 (1.85) 0.85

Dividend

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric TEVA UTHR Drug Manufacturers Specialty & Generic median
Market cap 46.87b 20.25b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack